<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00924053</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1474-C-396</org_study_id>
    <nct_id>NCT00924053</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Phase I, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of EGT0001474 in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and pharmacokinetics (how
      much of the drug gets into the blood and how long it takes the body to get rid of it) of
      single doses of EGT0001474 given to patients with Type 2 diabetes. The study will also
      evaluate how EGT0001474 affects the amount of glucose produced by the body in the urine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EGT0001474 is a compound that may inhibit the effect of other compounds in the body known as
      sugar transporters. The use of EGT0001474 may enhance the elimination of glucose from the
      blood by increasing the amount of urine produced. This would help prevent an abnormal
      decrease in blood sugar (hypoglycemia) both during fasting and after meals without increasing
      insulin secretion (which may result in weight gain or an abnormal increase in blood sugar
      known as Type 2 diabetes).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of EGT0001474</measure>
    <time_frame>25 days</time_frame>
    <description>Safety and tolerability were measured in terms of the number of mild, moderate and severe adverse events experienced by any participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-t</measure>
    <time_frame>3 days</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to time t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24</measure>
    <time_frame>3 days</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to hour 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC Inf</measure>
    <time_frame>3 days</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>3 days</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>3 days</time_frame>
    <description>Time of maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Î»z</measure>
    <time_frame>3 days</time_frame>
    <description>Terminal phase rate constant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>3 days</time_frame>
    <description>Apparent terminal half life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>3 days</time_frame>
    <description>The apparent rate of oral clearance of EGT0001474.Oral clearance was defined as rate of drug removal from the body after oral administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F</measure>
    <time_frame>3 days</time_frame>
    <description>Apparent volume of distribution</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>EGT0001474</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGT0001474</intervention_name>
    <description>Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.</description>
    <arm_group_label>EGT0001474</arm_group_label>
    <other_name>Human SGLT2 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules to match EGT0001474</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Human SGLT2 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or females between the ages of 18 to 70 diagnosed with Type 2 diabetes.

          -  Body mass Index (BMI) between 18 kg/m2 and 37 kg/m2.

          -  HbA1c levels between 6.5 and 9.0 (inclusive) where the upper limit of normal for the
             HbA1c assay is 6.4% or 6.2-9.0% (inclusive) where the upper limit of normal for the
             HbA1c assay is 6.1% and fasting plasma glucose between 110 and 240 mg/dL (inclusive)
             while on diabetic medications.

          -  If taking drugs for diabetes, must be medically able and willing to discontinue
             diabetes medications for the duration of the study.

          -  Female subjects must be surgically sterilized or postmenopausal.

          -  Non-smoker for at least 3 months.

          -  Negative alcohol screen.

        Exclusion Criteria:

          -  Type 1 diabetes.

          -  Use of insulin therapy or oral antidiabetic medication other than metformin,
             sitagliptin or a sulfonylurea.

          -  Sitting blood pressure above 150/95 mmHg on 2 evaluations at least 10 minutes apart at
             screening.

          -  Treatment with an investigational drug within 30 days or 7 half-lives, whichever is
             longer.

          -  Previous treatment with EGT0001474.

          -  Vaccination within 30 days prior to the first dose of study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mason W. Freeman, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>dgd Research Inc., a Cetero Research Company</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Blondel O, Bailbe D, Portha B. Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment. Metabolism. 1990 Aug;39(8):787-93.</citation>
    <PMID>2198430</PMID>
  </reference>
  <reference>
    <citation>Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care. 2006 Jun;29(6):1263-8.</citation>
    <PMID>16732006</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Review. Erratum in: Diabetes Care. 2008 Jun;31(6):1271.</citation>
    <PMID>18308683</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. Standards of medical care in diabetes--2008. Diabetes Care. 2008 Jan;31 Suppl 1:S12-54. doi: 10.2337/dc08-S012.</citation>
    <PMID>18165335</PMID>
  </reference>
  <reference>
    <citation>Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):31-8. Review.</citation>
    <PMID>15624123</PMID>
  </reference>
  <reference>
    <citation>Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008 Jun;57(6):1723-9. doi: 10.2337/db07-1472. Epub 2008 Mar 20.</citation>
    <PMID>18356408</PMID>
  </reference>
  <reference>
    <citation>Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008 Aug;62(8):1279-84. doi: 10.1111/j.1742-1241.2008.01829.x. Review.</citation>
    <PMID>18705823</PMID>
  </reference>
  <reference>
    <citation>Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009 May;85(5):513-9. doi: 10.1038/clpt.2008.250. Epub 2009 Jan 7. Erratum in: Clin Pharmacol Ther. 2009 May;85(5):558.</citation>
    <PMID>19129749</PMID>
  </reference>
  <reference>
    <citation>Krook A, Kawano Y, Song XM, EfendiÄ S, Roth RA, Wallberg-Henriksson H, Zierath JR. Improved glucose tolerance restores insulin-stimulated Akt kinase activity and glucose transport in skeletal muscle from diabetic Goto-Kakizaki rats. Diabetes. 1997 Dec;46(12):2110-4.</citation>
    <PMID>9392506</PMID>
  </reference>
  <reference>
    <citation>Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, Matsumoto M, Saito A, Tsujihara K, Anai M, Asano T, Kanai Y, Endou H. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800.</citation>
    <PMID>10480610</PMID>
  </reference>
  <reference>
    <citation>Pajor AM, Wright EM. Cloning and functional expression of a mammalian Na+/nucleoside cotransporter. A member of the SGLT family. J Biol Chem. 1992 Feb 25;267(6):3557-60.</citation>
    <PMID>1740408</PMID>
  </reference>
  <reference>
    <citation>Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003 Nov;14(11):2873-82.</citation>
    <PMID>14569097</PMID>
  </reference>
  <reference>
    <citation>Toggenburger G, Kessler M, Semenza G. Phlorizin as a probe of the small-intestinal Na+,D-glucose cotransporter. A model. Biochim Biophys Acta. 1982 Jun 14;688(2):557-71.</citation>
    <PMID>7201854</PMID>
  </reference>
  <reference>
    <citation>Tsujihara K, Hongu M, Saito K, Inamasu M, Arakawa K, Oku A, Matsumoto M. Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo). 1996 Jun;44(6):1174-80.</citation>
    <PMID>8814948</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <results_first_submitted>October 25, 2010</results_first_submitted>
  <results_first_submitted_qc>July 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2011</results_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled on 12 Jun 2009; the last subject was completed on 28 Jul 2009. Subjects participated at a CRO in San Antonio, TX.</recruitment_details>
      <pre_assignment_details>For 3 weeks after enrollment and prior to assignment to treatment and receiving drug, subjects were screened (informed consent, medical history, vital signs, electrocardiogram, laboratory test results, and screening for drugs of abuse and alcohol use) and began a 14 day washout period (counseling, review of medications and adverse events).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Received 1, 3, or 6 placebo capsules once daily.</description>
        </group>
        <group group_id="P2">
          <title>EGT0001474 25 mg</title>
          <description>Received one 25 mg capsule once daily.</description>
        </group>
        <group group_id="P3">
          <title>EGT0001474 75 mg</title>
          <description>Received three 25mg capsules once daily.</description>
        </group>
        <group group_id="P4">
          <title>EGT0001474 150mg</title>
          <description>Received six 25 mg capsules once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Received 1, 3, or 6 placebo capsules once daily.</description>
        </group>
        <group group_id="B2">
          <title>EGT0001474 25 mg</title>
          <description>Received one 25 mg capsule once daily.</description>
        </group>
        <group group_id="B3">
          <title>EGT0001474 75 mg</title>
          <description>Received three 25mg capsules once daily.</description>
        </group>
        <group group_id="B4">
          <title>EGT0001474 150mg</title>
          <description>Received six 25 mg capsules once daily.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of EGT0001474</title>
        <description>Safety and tolerability were measured in terms of the number of mild, moderate and severe adverse events experienced by any participants.</description>
        <time_frame>25 days</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received 1, 3, or 6 placebo capsules once daily.</description>
          </group>
          <group group_id="O2">
            <title>EGT0001474 25 mg</title>
            <description>Received one 25 mg capsule once daily.</description>
          </group>
          <group group_id="O3">
            <title>EGT0001474 75 mg</title>
            <description>Received three 25mg capsules once daily.</description>
          </group>
          <group group_id="O4">
            <title>EGT0001474 150mg</title>
            <description>Received six 25 mg capsules once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of EGT0001474</title>
          <description>Safety and tolerability were measured in terms of the number of mild, moderate and severe adverse events experienced by any participants.</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC 0-t</title>
        <description>Area under the plasma concentration-time curve from time 0 to time t</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received 1, 3, or 6 placebo capsules once daily.</description>
          </group>
          <group group_id="O2">
            <title>EGT0001474 25 mg</title>
            <description>Received one 25 mg capsule once daily.</description>
          </group>
          <group group_id="O3">
            <title>EGT0001474 75 mg</title>
            <description>Received three 25mg capsules once daily.</description>
          </group>
          <group group_id="O4">
            <title>EGT0001474 150mg</title>
            <description>Received six 25 mg capsules once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-t</title>
          <description>Area under the plasma concentration-time curve from time 0 to time t</description>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Placebo did not receive EGT0001474 drug</measurement>
                    <measurement group_id="O2" value="1103.89" spread="470.31"/>
                    <measurement group_id="O3" value="3370.29" spread="499.36"/>
                    <measurement group_id="O4" value="6177.8" spread="1691.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-24</title>
        <description>Area under the plasma concentration-time curve from time 0 to hour 24</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received 1, 3, or 6 placebo capsules once daily.</description>
          </group>
          <group group_id="O2">
            <title>EGT0001474 25 mg</title>
            <description>Received one 25 mg capsule once daily.</description>
          </group>
          <group group_id="O3">
            <title>EGT0001474 75 mg</title>
            <description>Received three 25mg capsules once daily.</description>
          </group>
          <group group_id="O4">
            <title>EGT0001474 150mg</title>
            <description>Received six 25 mg capsules once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24</title>
          <description>Area under the plasma concentration-time curve from time 0 to hour 24</description>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Placebo did not receive EGT0001474 drug</measurement>
                    <measurement group_id="O2" value="987.3" spread="368.21"/>
                    <measurement group_id="O3" value="2990.63" spread="461.18"/>
                    <measurement group_id="O4" value="5584.72" spread="1516.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC Inf</title>
        <description>Area under the plasma concentration-time curve from time 0 to infinity</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received 1, 3, or 6 placebo capsules once daily.</description>
          </group>
          <group group_id="O2">
            <title>EGT0001474 25 mg</title>
            <description>Received one 25 mg capsule once daily.</description>
          </group>
          <group group_id="O3">
            <title>EGT0001474 75 mg</title>
            <description>Received three 25mg capsules once daily.</description>
          </group>
          <group group_id="O4">
            <title>EGT0001474 150mg</title>
            <description>Received six 25 mg capsules once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Inf</title>
          <description>Area under the plasma concentration-time curve from time 0 to infinity</description>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Placebo did not receive EGT0001474 drug</measurement>
                    <measurement group_id="O2" value="1165.59" spread="479.88"/>
                    <measurement group_id="O3" value="3532.02" spread="524.74"/>
                    <measurement group_id="O4" value="6399.55" spread="1736.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum plasma concentration</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received 1, 3, or 6 placebo capsules once daily.</description>
          </group>
          <group group_id="O2">
            <title>EGT0001474 25 mg</title>
            <description>Received one 25 mg capsule once daily.</description>
          </group>
          <group group_id="O3">
            <title>EGT0001474 75 mg</title>
            <description>Received three 25mg capsules once daily.</description>
          </group>
          <group group_id="O4">
            <title>EGT0001474 150mg</title>
            <description>Received six 25 mg capsules once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum plasma concentration</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Placebo did not receive EGT0001474 drug</measurement>
                    <measurement group_id="O2" value="157.23" spread="76.25"/>
                    <measurement group_id="O3" value="518.67" spread="176.36"/>
                    <measurement group_id="O4" value="1014" spread="372.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>Time of maximum plasma concentration</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received 1, 3, or 6 placebo capsules once daily.</description>
          </group>
          <group group_id="O2">
            <title>EGT0001474 25 mg</title>
            <description>Received one 25 mg capsule once daily.</description>
          </group>
          <group group_id="O3">
            <title>EGT0001474 75 mg</title>
            <description>Received three 25mg capsules once daily.</description>
          </group>
          <group group_id="O4">
            <title>EGT0001474 150mg</title>
            <description>Received six 25 mg capsules once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time of maximum plasma concentration</description>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Placebo did not receive EGT0001474 drug</measurement>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O3" value="2" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O4" value="2" lower_limit="0.5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Î»z</title>
        <description>Terminal phase rate constant</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received 1, 3, or 6 placebo capsules once daily.</description>
          </group>
          <group group_id="O2">
            <title>EGT0001474 25 mg</title>
            <description>Received one 25 mg capsule once daily.</description>
          </group>
          <group group_id="O3">
            <title>EGT0001474 75 mg</title>
            <description>Received three 25mg capsules once daily.</description>
          </group>
          <group group_id="O4">
            <title>EGT0001474 150mg</title>
            <description>Received six 25 mg capsules once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Î»z</title>
          <description>Terminal phase rate constant</description>
          <units>1/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Placebo did not receive EGT0001474 drug</measurement>
                    <measurement group_id="O2" value="0.0741" spread="0.0215"/>
                    <measurement group_id="O3" value="0.0613" spread="0.0168"/>
                    <measurement group_id="O4" value="0.0622" spread="0.0195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2</title>
        <description>Apparent terminal half life</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received 1, 3, or 6 placebo capsules once daily.</description>
          </group>
          <group group_id="O2">
            <title>EGT0001474 25 mg</title>
            <description>Received one 25 mg capsule once daily.</description>
          </group>
          <group group_id="O3">
            <title>EGT0001474 75 mg</title>
            <description>Received three 25mg capsules once daily.</description>
          </group>
          <group group_id="O4">
            <title>EGT0001474 150mg</title>
            <description>Received six 25 mg capsules once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>Apparent terminal half life</description>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Placebo did not receive EGT0001474 drug</measurement>
                    <measurement group_id="O2" value="10.1" spread="3.21"/>
                    <measurement group_id="O3" value="12.18" spread="3.88"/>
                    <measurement group_id="O4" value="12.15" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F</title>
        <description>The apparent rate of oral clearance of EGT0001474.Oral clearance was defined as rate of drug removal from the body after oral administration.</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received 1, 3, or 6 placebo capsules once daily.</description>
          </group>
          <group group_id="O2">
            <title>EGT0001474 25 mg</title>
            <description>Received one 25 mg capsule once daily.</description>
          </group>
          <group group_id="O3">
            <title>EGT0001474 75 mg</title>
            <description>Received three 25mg capsules once daily.</description>
          </group>
          <group group_id="O4">
            <title>EGT0001474 150mg</title>
            <description>Received six 25 mg capsules once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F</title>
          <description>The apparent rate of oral clearance of EGT0001474.Oral clearance was defined as rate of drug removal from the body after oral administration.</description>
          <units>mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Placebo did not receive EGT0001474 drug</measurement>
                    <measurement group_id="O2" value="24479.26" spread="9146.52"/>
                    <measurement group_id="O3" value="21616.42" spread="3112.38"/>
                    <measurement group_id="O4" value="24996.33" spread="7009.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vz/F</title>
        <description>Apparent volume of distribution</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received 1, 3, or 6 placebo capsules once daily.</description>
          </group>
          <group group_id="O2">
            <title>EGT0001474 25 mg</title>
            <description>Received one 25 mg capsule once daily.</description>
          </group>
          <group group_id="O3">
            <title>EGT0001474 75 mg</title>
            <description>Received three 25mg capsules once daily.</description>
          </group>
          <group group_id="O4">
            <title>EGT0001474 150mg</title>
            <description>Received six 25 mg capsules once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F</title>
          <description>Apparent volume of distribution</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Placebo did not receive EGT0001474 drug</measurement>
                    <measurement group_id="O2" value="348376.12" spread="15666.55"/>
                    <measurement group_id="O3" value="382783.75" spread="138953.19"/>
                    <measurement group_id="O4" value="435944.78" spread="179821.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>25 days total (14 day washout, 4 days in study, 1 week follow up after dosing)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Received 1, 3, or 6 placebo capsules once daily.</description>
        </group>
        <group group_id="E2">
          <title>EGT0001474 25 mg</title>
          <description>Received one 25 mg capsule once daily.</description>
        </group>
        <group group_id="E3">
          <title>EGT0001474 75 mg</title>
          <description>Received three 25mg capsules once daily.</description>
        </group>
        <group group_id="E4">
          <title>EGT0001474 150mg</title>
          <description>Received six 25 mg capsules once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vessel puncture site reaction</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglyceride increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yuan-Di Halvorsen</name_or_title>
      <organization>Theracos, Inc</organization>
      <phone>617 726-4236</phone>
      <email>yhalvorsen@ccib.mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

